In the past week, MREO stock has gone down by -11.81%, with a monthly decline of -17.86% and a quarterly surge of 3.79%. The volatility ratio for the week is 5.97%, and the volatility levels for the last 30 days are 6.70% for Mereo Biopharma Group Plc ADR The simple moving average for the past 20 days is -8.47% for MREO’s stock, with a 29.85% simple moving average for the past 200 days.
Is It Worth Investing in Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Right Now?
The 36-month beta value for MREO is at 0.80. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MREO is 140.06M, and currently, shorts hold a 1.66% of that float. The average trading volume for MREO on April 11, 2024 was 1.75M shares.
MREO) stock’s latest price update
The stock price of Mereo Biopharma Group Plc ADR (NASDAQ: MREO) has plunged by -2.21 when compared to previous closing price of 2.94, but the company has seen a -11.81% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2024-03-14 that Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy, RNA editing, gene therapy, and RNA interference.
Analysts’ Opinion of MREO
Many brokerage firms have already submitted their reports for MREO stocks, with BTIG Research repeating the rating for MREO by listing it as a “Buy.” The predicted price for MREO in the upcoming period, according to BTIG Research is $4 based on the research report published on October 13, 2023 of the previous year 2023.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see MREO reach a price target of $4. The rating they have provided for MREO stocks is “Overweight” according to the report published on August 12th, 2022.
BTIG Research gave a rating of “Buy” to MREO, setting the target price at $10 in the report published on May 05th of the previous year.
MREO Trading at -18.18% from the 50-Day Moving Average
After a stumble in the market that brought MREO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.06% of loss for the given period.
Volatility was left at 6.70%, however, over the last 30 days, the volatility rate increased by 5.97%, as shares sank -9.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.98% lower at present.
During the last 5 trading sessions, MREO fell by -11.41%, which changed the moving average for the period of 200-days by +134.80% in comparison to the 20-day moving average, which settled at $3.13. In addition, Mereo Biopharma Group Plc ADR saw 24.46% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MREO
Current profitability levels for the company are sitting at:
- -4.7 for the present operating margin
- 0.64 for the gross margin
The net margin for Mereo Biopharma Group Plc ADR stands at -3.56. The total capital return value is set at -0.72. Equity return is now at value -39.59, with -26.75 for asset returns.
Based on Mereo Biopharma Group Plc ADR (MREO), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -6.27. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -14.83.
Currently, EBITDA for the company is -23.95 million with net debt to EBITDA at 1.27. When we switch over and look at the enterprise to sales, we see a ratio of 42.64. The receivables turnover for the company is 2.36for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.11.
Conclusion
In conclusion, Mereo Biopharma Group Plc ADR (MREO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
